Regencell Bioscience Holdings Limited (RGC) Q4 2024 earnings summary

Executive summary

• Regencell Bioscience Holdings is an early-stage bioscience company focused on developing and commercializing Traditional Chinese Medicine (TCM) for ADHD and ASD, with operations based in Hong Kong and no revenue generated to date.

• The company completed its IPO in July 2021, raising net proceeds of $22.67 million, and had $8.0 million in cash and short-term investments as of June 30, 2024.

• Three standardized TCM formulae candidates for ADHD and ASD are under development, with ongoing efficacy trials and plans for commercialization in Hong Kong pending regulatory approval.

• The company is led by CEO Yat-Gai Au, who, through Regencell (BVI) Limited, controls over 81% of the outstanding shares.

Financial highlights

• No revenue was generated for the years ended June 30, 2024, 2023, and 2022.

• Net loss was $4.36 million for FY2024, $6.06 million for FY2023, and $7.59 million for FY2022, reflecting ongoing R&D and administrative expenses.

• Operating expenses decreased 24% year-over-year to $4.74 million in FY2024, driven by lower G&A and R&D costs.

• Cash and short-term investments totaled $8.0 million as of June 30, 2024, down from $11.6 million a year earlier.

• No provision for income taxes was recorded due to ongoing losses and full valuation allowance on deferred tax assets.

Outlook and guidance

• Management believes current cash and short-term investments are sufficient to fund operations for at least the next twelve months.

• The company plans to continue R&D, pursue regulatory approval, and commercialize its TCM formulae in Hong Kong, with potential expansion to other markets after local commercialization.